Baidu
map

JAMA Cardiol:心脏病发作出院后高强度他汀类药物不能停

2017-04-20 枫丹白露 来宝网

根据JAMA心脏病学杂志发表的一项研究,住院治疗心脏病后的患者被给予高强度他汀类药物,在出院后两年,大部分患者没有继续服用高剂量的该药物。


根据JAMA心脏病学杂志发表的一项研究,住院治疗心脏病后的患者被给予高强度他汀类药物,在出院后两年,大部分患者没有继续服用高剂量的该药物。

高强度的他汀类药物被推荐用于治疗心肌梗塞(MI;心脏病发作)。纽约西奈山伊坎医学院罗伯特·罗森森博士及其同事进行了一项研究,其中包括在2007年至2012年期间66至75岁(n = 29,932)和75岁以上(n = 27,956)住院的医保受益人,在出院后30天内服用高强度他汀类药物(阿托伐他汀,40-80mg,瑞舒伐他汀,20-40mg)。受益人享有医疗保险免费服务的福利,包括医药费用。

66?75岁的患者出院6个月和2年后,分别有59%和42%的患者服用高强度的他汀类药物(占比最高达80%),比最初下降8.7%和13% (转为服用低至中等强度的他汀类药物,占有率至少为80%),分别有17%和19%的患者依从性较差(对于任何他汀类药物强度而言,中止时间的比例不超过80%),,分别有12%和19%的患者没有继续服用他汀类药物(在每个随访期间的最后60天没有他汀类药物可以服用)。

2007年至2012年期间服用高强度他汀类药物的患者比例有所增加。非裔美国人和西班牙裔患者和新的高强度他汀类药物使用者不太可能高度依从性地服用高强度他汀类药物,而具有双重医疗保险/医疗保险覆盖率和出院后更频繁拜访心脏病医生的患者,以及参与心脏康复的患者更有可能高度依从性地服用高强度的他汀类药物。 这些结果与在75岁以上医保受益者中的研究结果相似。

作者写道:“降低药物成本,拜访心脏病医生以及参与心脏康复可能有助于改善心肌梗死后高强度他汀类药物的使用和依从性。

原始出处:

Colantonio LD, MSc1 MD, Huang L, et al. Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries. JAMA Cardiology. Published online April 19, 2017; DOI: 10.1001/jamacardio.2017.0911

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044446, encodeId=2b87204444694, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Feb 28 16:11:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781746, encodeId=918e1e81746fb, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 13 20:11:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189866, encodeId=dabe1898666b, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sun Apr 23 11:42:16 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603997, encodeId=306b160399ec1, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Apr 22 13:11:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189555, encodeId=6d5c18955550, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sat Apr 22 07:20:28 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189263, encodeId=bec5189263a8, content=关键持续多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 07:47:28 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189258, encodeId=026818925850, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 21 07:41:47 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189189, encodeId=39c1189189a9, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Fri Apr 21 00:12:28 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044446, encodeId=2b87204444694, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Feb 28 16:11:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781746, encodeId=918e1e81746fb, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 13 20:11:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189866, encodeId=dabe1898666b, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sun Apr 23 11:42:16 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603997, encodeId=306b160399ec1, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Apr 22 13:11:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189555, encodeId=6d5c18955550, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sat Apr 22 07:20:28 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189263, encodeId=bec5189263a8, content=关键持续多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 07:47:28 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189258, encodeId=026818925850, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 21 07:41:47 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189189, encodeId=39c1189189a9, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Fri Apr 21 00:12:28 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044446, encodeId=2b87204444694, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Feb 28 16:11:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781746, encodeId=918e1e81746fb, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 13 20:11:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189866, encodeId=dabe1898666b, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sun Apr 23 11:42:16 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603997, encodeId=306b160399ec1, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Apr 22 13:11:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189555, encodeId=6d5c18955550, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sat Apr 22 07:20:28 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189263, encodeId=bec5189263a8, content=关键持续多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 07:47:28 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189258, encodeId=026818925850, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 21 07:41:47 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189189, encodeId=39c1189189a9, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Fri Apr 21 00:12:28 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-23 往日如昨

    继续学习中,谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2044446, encodeId=2b87204444694, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Feb 28 16:11:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781746, encodeId=918e1e81746fb, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 13 20:11:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189866, encodeId=dabe1898666b, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sun Apr 23 11:42:16 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603997, encodeId=306b160399ec1, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Apr 22 13:11:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189555, encodeId=6d5c18955550, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sat Apr 22 07:20:28 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189263, encodeId=bec5189263a8, content=关键持续多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 07:47:28 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189258, encodeId=026818925850, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 21 07:41:47 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189189, encodeId=39c1189189a9, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Fri Apr 21 00:12:28 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-22 aids219
  5. [GetPortalCommentsPageByObjectIdResponse(id=2044446, encodeId=2b87204444694, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Feb 28 16:11:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781746, encodeId=918e1e81746fb, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 13 20:11:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189866, encodeId=dabe1898666b, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sun Apr 23 11:42:16 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603997, encodeId=306b160399ec1, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Apr 22 13:11:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189555, encodeId=6d5c18955550, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sat Apr 22 07:20:28 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189263, encodeId=bec5189263a8, content=关键持续多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 07:47:28 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189258, encodeId=026818925850, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 21 07:41:47 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189189, encodeId=39c1189189a9, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Fri Apr 21 00:12:28 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-22 flysky120

    学习知识了,谢谢

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2044446, encodeId=2b87204444694, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Feb 28 16:11:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781746, encodeId=918e1e81746fb, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 13 20:11:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189866, encodeId=dabe1898666b, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sun Apr 23 11:42:16 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603997, encodeId=306b160399ec1, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Apr 22 13:11:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189555, encodeId=6d5c18955550, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sat Apr 22 07:20:28 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189263, encodeId=bec5189263a8, content=关键持续多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 07:47:28 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189258, encodeId=026818925850, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 21 07:41:47 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189189, encodeId=39c1189189a9, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Fri Apr 21 00:12:28 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-21 lovetcm

    关键持续多久?

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2044446, encodeId=2b87204444694, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Feb 28 16:11:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781746, encodeId=918e1e81746fb, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 13 20:11:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189866, encodeId=dabe1898666b, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sun Apr 23 11:42:16 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603997, encodeId=306b160399ec1, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Apr 22 13:11:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189555, encodeId=6d5c18955550, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sat Apr 22 07:20:28 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189263, encodeId=bec5189263a8, content=关键持续多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 07:47:28 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189258, encodeId=026818925850, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 21 07:41:47 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189189, encodeId=39c1189189a9, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Fri Apr 21 00:12:28 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-21 tofsw

    学习了谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2044446, encodeId=2b87204444694, content=<a href='/topic/show?id=644725344b1' target=_blank style='color:#2F92EE;'>#他汀类药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25344, encryptionId=644725344b1, topicName=他汀类药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Wed Feb 28 16:11:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1781746, encodeId=918e1e81746fb, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat May 13 20:11:00 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189866, encodeId=dabe1898666b, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Sun Apr 23 11:42:16 CST 2017, time=2017-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603997, encodeId=306b160399ec1, content=<a href='/topic/show?id=67b81023e6ea' target=_blank style='color:#2F92EE;'>#高强度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102376, encryptionId=67b81023e6ea, topicName=高强度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79d219134728, createdName=aids219, createdTime=Sat Apr 22 13:11:00 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189555, encodeId=6d5c18955550, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Sat Apr 22 07:20:28 CST 2017, time=2017-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189263, encodeId=bec5189263a8, content=关键持续多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Apr 21 07:47:28 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189258, encodeId=026818925850, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74221626377, createdName=tofsw, createdTime=Fri Apr 21 07:41:47 CST 2017, time=2017-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189189, encodeId=39c1189189a9, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K46ZAxBHmHsph32KkfsWGwmickB6RsCUD8KruE4vo5CpvXfdu16GBpp4ibh6WJu1o9iatP1LWKDmvmic/0, createdBy=be6f1940165, createdName=1e0ece0dm09(暂无匿称), createdTime=Fri Apr 21 00:12:28 CST 2017, time=2017-04-21, status=1, ipAttribution=)]
    2017-04-21 1e0ece0dm09(暂无匿称)

    谢谢分享谢谢分享

    0

相关资讯

2016AHA科学声明:他汀类和选择性应用心血管疾病的药物之间相互作用的管理建议发布

2016年10月,美国心脏协会(AHA)发布了关于他汀类和选择性应用心血管疾病的药物之间相互作用的管理建议声明,文章回顾了基本药物相互作用,各种他汀类药物的药理作用以及他汀类药物与选择用于治疗心血管疾病药物之间重要的相互作用。针对这些药物相互作用的临床管理提出了建议。全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

J Intern Med:啥?胰岛素会增加糖尿病患者的癌症风险?

2型糖尿病(T2DM)是否会增加癌症风险,仍不清楚;不同降糖疗法如何影响癌症风险,也不知道。本研究的目的是,提供T2DM治疗、他汀类药物的使用和不同部位癌症间的所有可能联系。 研究纳入1847051例在2006-2007年住院的患者,评估了年龄和性别相关的共同发生的不同部位癌症的诊断与使用降糖药物和他汀类药物之间的联系。 患者用胰岛素或胰岛素促泌素,导致男性结肠癌、肝癌、胰腺癌、肺癌和

Atherosclerosis:高冠脉钙化的患者应服用他汀药物治疗

背景:伴或不伴冠状动脉钙化(CAC)的符合他汀类药物治疗的患者,服用汀类药物治疗的疗效尚不清楚。本研究旨在评估心血管危险因素如何影响应用他汀类药物做为一级预防,及有无他汀类药物治疗CAC修订的临床预后。方法:研究者对圣弗兰西斯心脏研究临床试验进行Post-hoc分析,这项研究是一项双盲、安慰剂对照的随机对照试验,对CAC≥80%的无症状990例受试者每日分别予阿托伐他汀(20mg)、维生素C(1g

盘点丨“他汀类药物”的益处多到你想都想不到

他汀类药物是临床上最常见的降胆固醇的处方药,用于治疗和预防各种心血管疾病与高脂血症。这些年关于他汀类药物的研究实在是太多了,他汀类药物对人类健康的益处也实在是太多了,小编就把2016年的相关研究盘点给大家,只是2016年的哦~ 1-FCVB 2016:他汀类药物能降低常见癌症的死亡率吗? 英国伯明翰阿斯顿大学的研究人员对近100万名患者随访14年后发现,诊断高胆固醇的肺癌患者其死亡

PLoS One:早期慢性肾病患者使用他汀类药物:利 or 弊?

血脂异常可能会加速CKD进展,使用他汀类药物有助于改善肾功能,但CKD 患者使用他汀类药物的适应证尚不十分明确。近日,韩国嘉泉大学(Gachon University)的Ji Yong Jung博士研究小组在 PLoS ONE 发表的研究表明,“早期慢性肾脏病(CKD)患者(1-3期,估计肾小球滤过率≥ 30 ml/min/1.73 m2)服用他汀类药物可延缓肾功能下降,降低全因死亡率。”该回顾性

他汀类药物治疗可降低AS+PsA患者的心血管风险和总死亡率

根据美国风湿病学会年会上提交的调查结果显示,使用他汀类药物可以让强直性脊柱炎+银屑病关节炎患者的死亡率下降32%。 Amar Oza博士和同事们对2904例强直性脊柱炎(AS)+银屑病关节炎(PsA)患者进行了研究,研究他汀类药物对这类患者的生存益处。 平均随访时间为5.3年,他汀类使用者中死亡人数为271例;对照组5.15年的随访期间内,死亡人数为376例。他汀类药物使用组的死亡率为

Baidu
map
Baidu
map
Baidu
map